Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 2.70M | 2.70M | -40.60M | -37.76M | -0.97 |
| 2023 FY | 1.34M | 1.34M | -15.77M | 5.53M | 0.14 |
| 2024 FY | — | -193.00K | -12.78M | -19.10M | -0.47 |
| 2025 FY | 2.00M | 13.00K | -15.09M | 64.05M | 1.53 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 161.64M | 10.49M | 40.46M | 894.00K | 151.81M |
| 2023 FY | 220.55M | 57.66M | 9.06M | 51.62M | 163.82M |
| 2024 FY | 155.28M | 9.93M | 54.42M | 372.00K | 146.27M |
| 2025 FY | 230.86M | 31.12M | 45.95M | 825.00K | 199.74M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -28.70M | -496.00K | -29.20M | — | -36.78M |
| 2023 FY | -10.30M | -254.00K | -10.55M | — | -31.41M |
| 2024 FY | -8.41M | -18.00K | -8.43M | — | 45.37M |
| 2025 FY | -9.15M | -1.93M | -11.08M | — | -8.47M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 469.14M | 429.57M | — | — | — |
| 2023 FY | 93.13M | 135.69M | — | — | — |
| 2024 FY | 98.80M | 44.76M | — | — | — |
| 2025 FY | 118.00M | 72.88M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | -30.00K | -2.49M | 13.29M | 0.32 |
| 2025 Q3 | — | -31.00K | -2.43M | 48.40M | 1.16 |
| 2025 Q4 | — | -30.00K | -5.67M | 10.01M | 0.23 |
| 2026 Q1 | — | -30.00K | -3.66M | 38.31M | 0.94 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 161.68M | 8.10M | 15.80M | 912.00K | 154.53M |
| 2025 Q3 | 220.49M | 18.16M | 52.18M | 860.00K | 203.28M |
| 2025 Q4 | 230.86M | 31.12M | 45.95M | 825.00K | 199.74M |
| 2026 Q1 | 268.85M | 30.57M | 13.20M | 761.00K | 238.28M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -3.57M | -4.03K | -3.57M | — | -58.72M |
| 2025 Q3 | -1.99M | -289.00 | -1.99M | — | 36.38M |
| 2025 Q4 | -466.00K | 202.00K | -264.00K | — | -6.23M |
| 2026 Q1 | -2.92M | -5.00K | -2.92M | — | -32.75M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 93.92M | 79.04M | — | — | — |
| 2025 Q3 | 110.24M | 58.92M | — | — | — |
| 2025 Q4 | 118.00M | 72.88M | — | — | — |
| 2026 Q1 | 138.63M | 126.19M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |